Does the media favor DNTH or VTRS?

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 3 mentions for Viatris. Viatris' average media sentiment score of 1.10 beat Dianthus Therapeutics' score of 1.08 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNTH or GMAB?

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.16 beat Dianthus Therapeutics' score of 1.08 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ASND or DNTH?

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 7 articles in the media. Dianthus Therapeutics' average media sentiment score of 1.08 beat Ascendis Pharma A/S's score of 1.01 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNTH or BBIO?

In the previous week, BridgeBio Pharma had 11 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 7 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.08 beat BridgeBio Pharma's score of 0.70 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNTH or ELAN?

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Elanco Animal Health. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 5 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Dianthus Therapeutics' score of 1.08 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dianthus Therapeutics (DNTH) Competitors

$98.64 +1.04 (+1.07%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$102.38 +3.74 (+3.79%)

As of 07/13/2026 06:18 PM Eastern

Compare

DNTH vs. VTRS, GMAB, ASND, BBIO, and ELAN

Should you buy Dianthus Therapeutics stock or one of its competitors? MarketBeat compares Dianthus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dianthus Therapeutics include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Dianthus Therapeutics compare to Viatris?

Dianthus Therapeutics (NASDAQ:DNTH) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Viatris has a net margin of -2.04% compared to Dianthus Therapeutics' net margin of -12,998.50%. Viatris' return on equity of 19.04% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Viatris	-2.04%	19.04%	7.62%

Dianthus Therapeutics presently has a consensus target price of $117.82, suggesting a potential upside of 19.44%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 6.77%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 3 mentions for Viatris. Viatris' average media sentiment score of 1.10 beat Dianthus Therapeutics' score of 1.08 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,643.46	-$162.34M	-$4.13	N/A
Viatris	$14.30B	1.33	-$3.51B	-$0.26	N/A

Dianthus Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Viatris has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Dianthus Therapeutics beats Viatris on 10 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Genmab A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Dianthus Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Genmab A/S has a net margin of 21.05% compared to Dianthus Therapeutics' net margin of -12,998.50%. Genmab A/S's return on equity of 15.34% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Genmab A/S	21.05%	15.34%	8.94%

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.16 beat Dianthus Therapeutics' score of 1.08 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics presently has a consensus target price of $117.82, suggesting a potential upside of 19.44%. Genmab A/S has a consensus target price of $38.21, suggesting a potential upside of 32.69%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Genmab A/S has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,643.46	-$162.34M	-$4.13	N/A
Genmab A/S	$3.72B	4.83	$963M	$1.32	21.82

Summary

Genmab A/S beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Ascendis Pharma A/S has a net margin of 57.87% compared to Dianthus Therapeutics' net margin of -12,998.50%. Ascendis Pharma A/S's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 7 articles in the media. Dianthus Therapeutics' average media sentiment score of 1.08 beat Ascendis Pharma A/S's score of 1.01 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.31	-$258M	$8.67	30.59
Dianthus Therapeutics	$2.04M	2,643.46	-$162.34M	-$4.13	N/A

47.5% of Dianthus Therapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ascendis Pharma A/S has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Ascendis Pharma A/S currently has a consensus target price of $295.67, indicating a potential upside of 11.48%. Dianthus Therapeutics has a consensus target price of $117.82, indicating a potential upside of 19.44%. Given Dianthus Therapeutics' higher possible upside, analysts plainly believe Dianthus Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Ascendis Pharma A/S beats Dianthus Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Dianthus Therapeutics (NASDAQ:DNTH) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Dianthus Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,643.46	-$162.34M	-$4.13	N/A
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A

BridgeBio Pharma has a net margin of -124.42% compared to Dianthus Therapeutics' net margin of -12,998.50%. BridgeBio Pharma's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
BridgeBio Pharma	-124.42%	N/A	-65.81%

In the previous week, BridgeBio Pharma had 11 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 7 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.08 beat BridgeBio Pharma's score of 0.70 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Dianthus Therapeutics currently has a consensus target price of $117.82, indicating a potential upside of 19.44%. BridgeBio Pharma has a consensus target price of $94.63, indicating a potential upside of 13.90%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Dianthus Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BridgeBio Pharma beats Dianthus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Elanco Animal Health?

Dianthus Therapeutics (NASDAQ:DNTH) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Elanco Animal Health has a net margin of -4.95% compared to Dianthus Therapeutics' net margin of -12,998.50%. Elanco Animal Health's return on equity of 7.42% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Elanco Animal Health	-4.95%	7.42%	3.66%

Dianthus Therapeutics currently has a consensus target price of $117.82, indicating a potential upside of 19.44%. Elanco Animal Health has a consensus target price of $28.55, indicating a potential upside of 13.61%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Dianthus Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dianthus Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,643.46	-$162.34M	-$4.13	N/A
Elanco Animal Health	$4.72B	2.66	-$232M	-$0.50	N/A

Dianthus Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Elanco Animal Health. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 5 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Dianthus Therapeutics' score of 1.08 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dianthus Therapeutics and Elanco Animal Health tied by winning 8 of the 16 factors compared between the two stocks.

Get Dianthus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNTH vs. The Competition

Export

Metric	Dianthus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.34B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-23.88	20.85	27.11	24.26
Price / Sales	2,643.46	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	8.65	8.49	10.75	6.29
Net Income	-$162.34M	$23.83M	$3.58B	$330.66M
7 Day Performance	3.01%	-3.56%	-2.06%	-1.32%
1 Month Performance	20.19%	6.31%	3.32%	-0.64%
1 Year Performance	392.46%	48.30%	26.36%	19.08%

Dianthus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNTH Dianthus Therapeutics	2.8348 of 5 stars	$98.64 +1.1%	$117.82 +19.4%	+391.7%	$5.34B	$2.04M	N/A	80	Positive News Insider Trade
VTRS Viatris	2.7092 of 5 stars	$16.96 +1.0%	$17.50 +3.2%	+79.7%	$19.56B	$14.30B	N/A	30,000
GMAB Genmab A/S	4.585 of 5 stars	$29.18 +4.2%	$38.21 +31.0%	+34.6%	$17.47B	$3.72B	22.11	3,029
ASND Ascendis Pharma A/S	4.3715 of 5 stars	$266.97 -0.4%	$295.67 +10.7%	+51.6%	$16.71B	$814.57M	30.79	1,189	Positive News
BBIO BridgeBio Pharma	3.1076 of 5 stars	$77.91 +0.2%	$92.90 +19.2%	+78.8%	$15.23B	$502.08M	N/A	400	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNTH) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. VTRS, GMAB, ASND, BBIO, and ELAN

How does Dianthus Therapeutics compare to Viatris?

Summary

How does Dianthus Therapeutics compare to Genmab A/S?

Summary

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Summary

How does Dianthus Therapeutics compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. VTRS, GMAB, ASND, BBIO, and ELAN

How does Dianthus Therapeutics compare to Viatris?

Is DNTH or VTRS more profitable?

Do analysts recommend DNTH or VTRS?

Does the media favor DNTH or VTRS?

Which has better valuation and earnings, DNTH or VTRS?

Which has more volatility & risk, DNTH or VTRS?

Do institutionals and insiders hold more shares of DNTH or VTRS?

Summary

How does Dianthus Therapeutics compare to Genmab A/S?

Which has more risk and volatility, DNTH or GMAB?

Do insiders & institutionals hold more shares of DNTH or GMAB?

Is DNTH or GMAB more profitable?

Does the media refer more to DNTH or GMAB?

Do analysts recommend DNTH or GMAB?

Which has better earnings & valuation, DNTH or GMAB?

Summary

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Is ASND or DNTH more profitable?

Does the media refer more to ASND or DNTH?

Which has higher earnings & valuation, ASND or DNTH?

Do insiders and institutionals believe in ASND or DNTH?

Which has more volatility and risk, ASND or DNTH?

Do analysts prefer ASND or DNTH?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Which has stronger earnings and valuation, DNTH or BBIO?

Is DNTH or BBIO more profitable?

Does the media prefer DNTH or BBIO?

Which has more risk and volatility, DNTH or BBIO?

Do analysts prefer DNTH or BBIO?

Do institutionals and insiders believe in DNTH or BBIO?

Summary

How does Dianthus Therapeutics compare to Elanco Animal Health?

Is DNTH or ELAN more profitable?

Do analysts rate DNTH or ELAN?

Do insiders and institutionals have more ownership in DNTH or ELAN?

Which has stronger earnings and valuation, DNTH or ELAN?

Which has more risk and volatility, DNTH or ELAN?

Does the media prefer DNTH or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools